Gastrectomy with D2 lymph node dissection has become the global standard procedure for locally advanced gastric cancer to maximally reduce locoregional recurrence. In East Asia, based on the evidence of the ACTS-GC and the CLASSIC trials, postadjuvant chemotherapy with S-1 monotherapy or capecitabine and oxaliplatin after curative D2 gastrectomy is the current standard strategy. However, approximately 20% to 30% of patients still develop distant recurrence even after these postadjuvant chemotherapies, especially in those with pathological stage III disease. 
physical examination, a phenomenon referred to as a recurrence.
The aims of adjuvant chemotherapy are "to cure" the macroscopic cancer after complete resection, whereby tumors that have grown to be macroscopically recognizable are no longer curable. 2, 3 The types of recurrence pattern after gastrectomy include locoregional recurrence, distant (lymph node or hematogenous) metastasis, and peritoneum metastasis. There are differences in the incidence of types of recurrence pattern between East Asian and Western patients with locally advanced gastric cancer. While locoregional recurrence and hematogenous metastasis are common in the United States, peritoneal, hematogenous, and lymph node metastasis are more common in East Asia. [4] [5] [6] Therefore, adjuvant chemotherapy is the standard therapeutic strategy following resection in Japan and South Korea in contrast to standard adjuvant chemoradiation in the United States.
Further, it is known that there are differences in efficacy among the anticancer agents and regimens of chemotherapy for the different recurrence patterns. In this review, we summarize recent (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) (2018) evidence on the benefits of adjuvant therapy for locally advanced gastric cancer from the viewpoint of the recurrence pattern.
| CURATIVE SURGERY WITH DLYMPH NODE DISSECTION
Complete surgical resection is the essential treatment for locally advanced gastric cancer. Because pathological lymph node metastasis in gastric cancer has been reported in about 15% of early gastric cancer and 40%-70% of pathological T2-4a tumors, gastrectomy with lymphadenectomy is necessary. 7 A follow-up report from a Dutch trial showed that gastric cancer-related death was significantly less after D2 as compared to D1 gastrectomy. 8 However, D2 plus para-aortic lymph node dissection did not improve the survival rate of patients with curable gastric cancer in a Phase III trial performed in Japan. 9 Given these facts, D2 gastrectomy has become the standard surgical procedure for locally advanced gastric cancer in East Asia, particularly in Japan and South Korea. 10, 11 This type of surgery is now also recommended in the United States and Europe as well. 12, 13 According to the results of two Phase III studies in Japan and Korea that showed a survival benefit for adjuvant chemotherapy following D2 gastrectomy compared with surgery alone for locally advanced gastric cancer, locoregional recurrence after 5-year follow-up in the surgery alone group was still satisfactory with a low incidence (3.2% vs 10.1%, respectively). 5, 6 These findings suggest that standardized D2 gastrectomy alone without adjuvant chemotherapy for locally advanced gastric cancer can adequately control locoregional recurrence. Hence, efficacy of adjuvant therapy should be discussed on the premise that locoregional recurrence can be maximally controlled by standardized D2 gastrectomy. (Table 1) . 5 In contrast, adjuvant treatment with capecitabine plus oxaliplatin had a smaller effect on peritoneal recurrence. 6 The possible reason for these differences in recurrent pattern is that clinical effect of adjuvant treatment is highly dependent on the efficiency of the drug delivery to recurrent organ sites.
| POSTADJUVANT CHEMOTHERAPY
Hence, adjuvant treatment should be considered according to the different pattern of recurrence in each patient.
| S-1-based doublet combination regimens
Subgroup analysis in the ACTS-GC trial showed that S-1 monotherapy reduced lymph node metastasis in both pStage II and III patients, while S-1 reduced peritoneal recurrence only in pStage II cases ( 
| Duration of postadjuvant chemotherapy
The Japan Clinical Oncology Group (JCOG) conducted the OPAS-I (JCOG1104) trial, a Phase III study, to evaluate the overall efficacy of four courses of S-1 adjuvant chemotherapy as compared to eight courses of the same regimen in patients who were diagnosed with pStage II after surgery. At the planned first interim, four courses of S-1 were inferior to eight courses of S-1 in terms of RFS, and the independent data and safety monitoring committee recommended termination of the trial. 19 The updated results of this trial were presented at the ASCO 2018 meeting. 20 The 3-year RFS was 89.8% for four courses and 93.1% for eight courses (HR: 1.84; 95% CI: 0.94-3.63), and the 3-year OS was 92.6% for the four courses and 96.1%
for the eight courses (HR: 3.34; 95% CI: 1.22-9.12) of treatment.
The cumulative incidence of recurrence at 3 years was 7.7% for the four courses and 5.5% for the eight courses (HR: 1.59; 95% CI: 0.75-3.39) of S-1. The 5-year follow-up report of the ACTS-GC trial showed improved survival in patients with postoperative administration of S-1 for one year compared with those who were administered for less than one year. 14 This report also showed poor 3-year survival rate in patients who were given S-1 at less than 70% dose More recently, as mentioned above, the JACRO phase III study reported that the 3-year RFS using six cycles of S-1/docetaxel followed by S-1 again was 65.9%. According to these findings, the recommended duration of postadjuvant chemotherapy after curative D2 gastrectomy is one year for S-1 monotherapy for pStage II disease and more than six cycles of S-1/docetaxel followed by S-1 for pStage III gastric cancer.
| Postadjuvant chemoradiation
Due to the lack of evidence regarding the effect of postadjuvant therapy with chemoradiation after D2 gastrectomy, postadjuvant chemotherapy is the standard strategy after D2 gastrectomy in Japan and Korea. The ARTIST trial in Korea was the first study con- patients after curative-resected gastric cancer with D2 gastrectomy. 24 This trial was designed to investigate the OS following post- two courses of S-1/cisplatin, followed by D2 plus para-aortic lymph node dissection. 25 A combination of S-1 (S-1 at 80-120 mg/body on days 1-21, every 28 days) and cisplatin (60 mg/m 2 on day 1), which is the standard first-line treatment for advanced/metastatic gastric cancer in Japan, was the administered regimen in this study. The R0 resection rate was 82%, and the 3-year and 5-year OS were unexpectedly high at 59 and 53%, respectively. Subsequently, another
Phase II trial for the bulky N population was conducted to evaluate neoadjuvant therapy using a triplet regimen with DCS (docetaxel at 40 mg/m 2 on day 1, cisplatin at 60 mg/m 2 on day 1, S-1 at 80-120 mg/body on days 1-14, every 28 days). 26 However, the response rate of this DCS regimen at 58% did not reach the expected value of 80%, thus, S-1/cisplatin remains the current standard. Neoadjuvant chemotherapy with S-1/cisplatin followed by D2
plus para-aortic lymph node dissection is now considered tentatively as the standard of care for this specific population. 27 The scirrhous type cancer, such as type 4 or large type 3 gastric cancer with >8 cm diameter, is characterized by poorly differentiated adenocarcinoma including the histological presence of signet ring cells and by frequent peritoneal recurrence. The JCOG0501 trial, a Phase 
| Neoadjuvant chemotherapy for clinical stage III cancer in Japan
Upon expanding the target of neoadjuvant chemotherapy to resectable advanced gastric cancer, there was a concern of the accuracy of preoperative staging. Thus, the JCOG1302-A trial was conducted to evaluate the accuracy of preoperative staging using multidetector computerized tomography and endoscopy. 29 The optimal preopera- 
| Perioperative chemotherapy in Europe

| Duration of neoadjuvant chemotherapy
The optimal regimen and number of courses for neoadjuvant therapy are issues to resolve. The COMPASS trial compared two and four courses of doublet neoadjuvant regimen with S-1/cisplatin and paclitaxel/cisplatin for a mixed population of patients with advanced gastric cancer (bulky N, type 4 or large type 3 cancer, and advanced junctional adenocarcinoma In East Asia, postadjuvant chemotherapy using S-1 monotherapy or capecitabine and oxaliplatin after curative D2 gastrectomy is the standard pre-emptive or facilitative strategy. 
